acetic acid-[4-(N-methyl-sulfanilyl)-anilide] | 123862-10-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetic acid-[4-(N-methyl-sulfanilyl)-anilide]
• 英文别名: Essigsaeure-[4-(N-methyl-sulfanilyl)-anilid]；Essigsaeure-[4-(4-methylamino-phenylsulfon)-anilid]；(4-Methylamino-phenyl)-(4-acetamino-phenyl)-sulfon；N-[4-[4-(methylamino)phenyl]sulfonylphenyl]acetamide
• CAS: 123862-10-2
• 化学式: C₁₅H₁₆N₂O₃S
• 分子量: 304.37
• InChiKey: NXCMODGGPJEVET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  acetic acid-[4-(N-methyl-sulfanilyl)-anilide] 在 盐酸 作用下， 生成 (4-amino-phenyl)-(4-methylamino-phenyl)-sulfone
  参考文献：
  名称：

  Derivatives of p,p'-Diaminodiphenyl Sulfone. II¹

  摘要：

  DOI：

  10.1021/ja01227a036
• 作为产物：
  描述：

  N-[4-(4-硝基苯基)磺酰基苯基]乙酰胺 在 吡啶 、 chromium(III) oxide 、 sodium hydroxide 、 copper(II) oxide 作用下， 240.0 ℃ 、13.73 MPa 条件下， 生成 acetic acid-[4-(N-methyl-sulfanilyl)-anilide]
  参考文献：
  名称：

  Derivatives of p,p'-Diaminodiphenyl Sulfone. II¹

  摘要：

  DOI：

  10.1021/ja01227a036

文献信息

• High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
  申请人：Techfields Pharma Co., Ltd.

  公开号：US11485744B2

  公开（公告）日：2022-11-01

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明提供了新型抗菌剂和抗菌剂相关化合物的高渗透组合物（HPC）或高渗透原药（HPP），它们能够以高渗透效率穿过生物屏障。HPCs/HPPs 在穿过生物屏障后能够转化为母体活性药物或药物代谢物，因此能够像母体药物或代谢物那样对病症进行治疗。此外，HPPs 还能进入母体药物可能无法进入的区域，或在目标区域产生足够的浓度，从而提供新的治疗方法。HPCs/HPPs 可通过各种给药途径给受试者用药，例如，以高浓度局部给药到疾病的作用部位，或系统地给生物受试者用药，并以更快的速度进入血液循环。
• US2382924
  申请人：——

  公开号：——

  公开（公告）日：——
• CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES
  申请人：Centro De Ingenieria Genetica Y Biotecnologia

  公开号：EP2258356B1

  公开（公告）日：2017-09-27
• HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS
  申请人：Techfields Pharma Co., Ltd.

  公开号：US20180222921A1

  公开（公告）日：2018-08-09

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
• HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS
  申请人：Techfields Pharma Co., Ltd.

  公开号：US20190142818A1

  公开（公告）日：2019-05-16

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.